Kim K - Search Results

1

Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial.

Yu JI, Choi C, Lee J, Kang WK, Park SH, Kim ST, Hong JY, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim KM, Han H, Kim K, Nam H, Lim DH. Yu JI, et al. Among authors: kim st, kim km, kim s, kim k. Radiother Oncol. 2020 Nov;152:19-25. doi: 10.1016/j.radonc.2020.07.043. Epub 2020 Jul 31. Radiother Oncol. 2020. PMID: 32739319 Clinical Trial.

2

AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.

Cho EY, Kim KM, Park CK, Kim JJ, Sohn TS, Kim DW. Cho EY, et al. APMIS. 2007 Jun;115(6):713-8. doi: 10.1111/j.1600-0463.2007.apm_639.x. APMIS. 2007. PMID: 17550379

3

Stage IV early gastric cancer: two cases with microsatellite instability.

An JY, Choi MG, Noh JH, Kim KM, Kim DS, Sohn TS, Kim S. An JY, et al. Langenbecks Arch Surg. 2008 Jan;393(1):105-9. doi: 10.1007/s00423-007-0228-8. Epub 2007 Oct 5. Langenbecks Arch Surg. 2008. PMID: 17917741

4

Clinical significance of tumor location in remnant gastric cancers developed after partial gastrectomy for primary gastric cancer.

An JY, Youn HG, Ha TK, Choi MG, Kim KM, Noh JH, Sohn TS, Kim S. An JY, et al. J Gastrointest Surg. 2008 Apr;12(4):689-94. doi: 10.1007/s11605-007-0437-z. Epub 2007 Dec 13. J Gastrointest Surg. 2008. PMID: 18080844

5

Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.

Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim DH, Kim KM, Kang WK. Lee J, et al. Clin Cancer Res. 2008 Jan 1;14(1):82-8. doi: 10.1158/1078-0432.CCR-07-0612. Clin Cancer Res. 2008. PMID: 18172256

6

Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.

Keun Park C, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH, Sohn TS, Kim S, Kim MJ, Lee HK, Kim KM. Keun Park C, et al. Ann Surg. 2008 Jun;247(6):1011-8. doi: 10.1097/SLA.0b013e3181724f9d. Ann Surg. 2008. PMID: 18520229

7

Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.

Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, Kim S, Kim MJ, Kim KM. Park ES, et al. Clin Cancer Res. 2009 Jan 1;15(1):291-8. doi: 10.1158/1078-0432.CCR-08-0848. Clin Cancer Res. 2009. PMID: 19118057

8

Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression.

Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, Kim KM, Sohn TS, Kim S. Choi MG, et al. J Surg Res. 2009 Dec;157(2):168-74. doi: 10.1016/j.jss.2008.06.020. Epub 2008 Jul 15. J Surg Res. 2009. PMID: 19559447

9

Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.

Choi D, Yoo EY, Kim KM, Sohn TS, Lee WJ, Lee JY, Chang I. Choi D, et al. AJR Am J Roentgenol. 2009 Aug;193(2):W100-5. doi: 10.2214/AJR.08.2106. AJR Am J Roentgenol. 2009. PMID: 19620409

10

Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma.

Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim DH, Kim KM, Park CK. Lee J, et al. APMIS. 2009 Aug;117(8):598-606. doi: 10.1111/j.1600-0463.2009.02512.x. APMIS. 2009. PMID: 19664131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51,699 results

Search Page